Trials / Completed
CompletedNCT07076056
Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2
A Randomized, Double-blind, Multi-center, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 Add-on to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sitagliptin Combination Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 230 (actual)
- Sponsor
- Daewon Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
A Randomized, Double-blind, Multi-center, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 Add-on to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sitagliptin Combination Therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DW1026C1 | Sitagliptin 100mg+Empagliflozin 10mg |
| DRUG | DW1026C2 | Sitagliptin 100mg+Empagliflozin 25mg |
| DRUG | DW1026S | Sitagliptin 100mg |
Timeline
- Start date
- 2022-10-27
- Primary completion
- 2023-12-04
- Completion
- 2024-06-19
- First posted
- 2025-07-21
- Last updated
- 2025-07-21
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07076056. Inclusion in this directory is not an endorsement.